A Pilot randomized control trial of hydrogen gas inhalation for oral mucositis from concurrent chemoradiation therapy (CCRT) in head and neck cancer

Status

Recruiting

Phases

Phase 2Phase 3

Study type

Interventional

Source

TCTR

Registry ID

TCTR20250726001

Enrollment

Registered

2025-07-26

Start date

2024-06-13

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

The rate of acute toxicity in locally advanced head and neck cancer patients who receive CCRT with or without H2 gas inhalation. Hydrogen gas, Hydrogen gas Inhalation, Concurrent chemoradiotherapy, Head and neck cancer

Interventions

CCRT with daily H2 gas inhalation,CCRT alone

Experimental Device,No Intervention Other

H2 gas inhalation,Control

Eligibility

Sex/Gender

All

Age

20 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Locally advanced head and neck cancer. 2. Plan to receive concurrent chemoradiation. 3. Eastern Cooperative Oncology Group (ECOG) performance status 0-2. 4. Able to provide informed consent.

Exclusion criteria

Exclusion criteria: 1. Prior radiotherapy to the head and neck region. 2. On tracheostomy tube.

Design outcomes

Primary

Measure	Time frame
Acute toxicity weekly Grade according to Common Terminology Criteria for Adverse Events	—

Secondary

Measure	Time frame
Tumor response 3 months post concurrent chemoradiation therapy Response Evaluation Criteria in Solid Tumors	—

Countries

Thailand

Contacts

Public ContactWimrak Onchan

Faculty of Medicine, Chiang Mai University

ai_name@hotmail.com053935456

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 10, 2026